Literature DB >> 18367581

Use of baculovirus-expressed glycoprotein H in an enzyme-linked immunosorbent assay developed to assess exposure to chelonid fibropapillomatosis-associated herpesvirus and its relationship to the prevalence of fibropapillomatosis in sea turtles.

Lawrence H Herbst1, Shefali Lemaire, Ada R Ene, David J Heslin, Llewellyn M Ehrhart, Dean A Bagley, Paul A Klein, Jack Lenz.   

Abstract

Chelonid fibropapillomatosis-associated herpesvirus (CFPHV) is an alphaherpesvirus believed to cause marine turtle fibropapillomatosis (FP). A serodiagnostic assay was developed for monitoring sea turtle populations for CFPHV exposure. CFPHV glycoprotein H (gH) expressed in recombinant baculovirus was used in an enzyme-linked immunosorbent assay (ELISA) to detect virus-specific 7S turtle antibodies. Using captive-reared green turtles (Chelonia mydas) with no history of virus exposure as "known negatives" and others with experimentally induced FP as "known positives," the assay had 100% specificity but low sensitivity, as seroconversion was detected in only half of the turtles bearing experimentally induced tumors. Antibodies were detected only in samples collected after cutaneous fibropapillomas appeared, consistent with observations that tumors are significant sites of virion production and antigen expression and the possibility that prolonged/repeated virus shedding may be required for adequate stimulation of 7S antibody responses to gH. Natural routes of infection, however, may produce higher seroconversion rates. High gH antibody seroprevalences ( approximately 80%) were found among wild green turtles in three Florida localities with different FP prevalences, including one site with no history of FP. In addition, all eight loggerhead turtles (Caretta caretta) tested were seropositive despite FP being uncommon in this species. The possibility that CFPHV infection may be common relative to disease suggests roles for environmental and host factors as modulators of disease expression. Alternatively, the possibility of other antigenically similar herpesviruses present in wild populations cannot be excluded, although antibody cross-reactivity with the lung/eye/trachea disease-associated herpesvirus was ruled out in this study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367581      PMCID: PMC2394848          DOI: 10.1128/CVI.00438-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  35 in total

1.  Verrucous herpes virus infection in human immunodeficiency virus patients.

Authors:  W A Fagan; P C Collins; D R Pulitzer
Journal:  Arch Pathol Lab Med       Date:  1996-10       Impact factor: 5.534

2.  Identification and expression of immunogenic proteins of a disease-associated marine turtle herpesvirus.

Authors:  Sadie S Coberley; Richard C Condit; Lawrence H Herbst; Paul A Klein
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  A herpesvirus-type agent associated with skin lesions of green sea turtles in aquaculture.

Authors:  G Rebell; A Rywlin; H Haines
Journal:  Am J Vet Res       Date:  1975-08       Impact factor: 1.156

4.  Identification of an Epstein-Barr virus glycoprotein which is antigenically homologous to the varicella-zoster virus glycoprotein II and the herpes simplex virus glycoprotein B.

Authors:  E A Emini; J Luka; M E Armstrong; P M Keller; R W Ellis; G R Pearson
Journal:  Virology       Date:  1987-04       Impact factor: 3.616

5.  Conjunctivitis, tracheitis, and pneumonia associated with herpesvirus infection in green sea turtles.

Authors:  E R Jacobson; J M Gaskin; M Roelke; E C Greiner; J Allen
Journal:  J Am Vet Med Assoc       Date:  1986-11-01       Impact factor: 1.936

6.  Three classes of immunoglobulins found in the sea turtle, Chelonia mydas.

Authors:  A A Benedict; L W Pollard
Journal:  Folia Microbiol (Praha)       Date:  1972       Impact factor: 2.099

7.  Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus.

Authors:  N Balachandran; D E Oba; L M Hutt-Fletcher
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

8.  HSV-1 gB and VZV gp-II crossreactive antibodies in human sera.

Authors:  J E Kühn; K Klaffke; K Munk; R W Braun
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

9.  Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB.

Authors:  K Kitamura; J Namazue; H Campo-Vera; T Ogino; K Yamanishi
Journal:  Virology       Date:  1986-02       Impact factor: 3.616

10.  Verrucous lesions secondary to DNA viruses in patients infected with the human immunodeficiency virus in association with increased factor XIIIa-positive dermal dendritic cells. The Military Medical Consortium of Applied Retroviral Research Washington, D.C.

Authors:  K J Smith; H G Skelton; D M Frissman; P Angritt
Journal:  J Am Acad Dermatol       Date:  1992-12       Impact factor: 11.527

View more
  13 in total

1.  Differences in Antibody Responses against Chelonid Alphaherpesvirus 5 (ChHV5) Suggest Differences in Virus Biology in ChHV5-Seropositive Green Turtles from Hawaii and ChHV5-Seropositive Green Turtles from Florida.

Authors:  Thierry M Work; Julie Dagenais; Anna Willimann; George Balazs; Kate Mansfield; Mathias Ackermann
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

Review 2.  Horizontal gene transfers with or without cell fusions in all categories of the living matter.

Authors:  Joseph G Sinkovics
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

3.  Morphologic and physiologic characteristics of green sea turtle (Chelonia mydas) hatchlings in southeastern Florida, USA.

Authors:  Annie Page-Karjian; Nicole I Stacy; Ashley N Morgan; Christina M Coppenrath; Charles A Manire; Lawrence H Herbst; Justin R Perrault
Journal:  J Comp Physiol B       Date:  2022-08-07       Impact factor: 2.230

4.  Preparation of recombinant glycoprotein B (gB) of Chelonid herpesvirus 5 (ChHV5) for antibody production and its application for infection detection in sea turtles.

Authors:  Tsung-Hsien Li; Wei-Li Hsu; Chang-You Chen; Yi-Chen Chen; Yu-Chen Wang; Ming-An Tsai; I-Chun Chen; Chao-Chin Chang
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

5.  Examining the Role of Transmission of Chelonid Alphaherpesvirus 5.

Authors:  Andrea Chaves; A Alonso Aguirre; Kinndle Blanco-Peña; Andrés Moreira-Soto; Otto Monge; Ana M Torres; José L Soto-Rivas; Yuanan Lu; Didiher Chacón; Luis Fonseca; Mauricio Jiménez; Gustavo Gutiérrez-Espeleta; Michael Lierz
Journal:  Ecohealth       Date:  2017-05-16       Impact factor: 3.184

6.  Chelonid Alphaherpesvirus 5 Prevalence and First Confirmed Case of Sea Turtle Fibropapillomatosis in Grenada, West Indies.

Authors:  Amanda James; Annie Page-Karjian; Kate E Charles; Jonnel Edwards; Christopher R Gregory; Sonia Cheetham; Brian P Buter; David P Marancik
Journal:  Animals (Basel)       Date:  2021-05-21       Impact factor: 2.752

7.  Presence of chelonid fibropapilloma-associated herpesvirus in tumored and non-tumored green turtles, as detected by polymerase chain reaction, in endemic and non-endemic aggregations, Puerto Rico.

Authors:  Annie Page-Karjian; Fernando Torres; Jian Zhang; Samuel Rivera; Carlos Diez; Phillip A Moore; Debra Moore; Corrie Brown
Journal:  Springerplus       Date:  2012-10-17

8.  A trade-off between natural and acquired antibody production in a reptile: implications for long-term resistance to disease.

Authors:  Franziska C Sandmeier; C Richard Tracy; Sally Dupré; Kenneth Hunter
Journal:  Biol Open       Date:  2012-08-28       Impact factor: 2.422

9.  Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.

Authors:  Rui-Chen Li; Yong Du; Qiu-Yao Zeng; Lin-Quan Tang; Hua Zhang; Yan Li; Wan-Li Liu; Qian Zhong; Mu-Sheng Zeng; Xiao-Ming Huang
Journal:  Oncotarget       Date:  2016-03-29

10.  Further evidence of Chelonid herpesvirus 5 (ChHV5) latency: high levels of ChHV5 DNA detected in clinically healthy marine turtles.

Authors:  Alonzo Alfaro-Núñez; Anders Miki Bojesen; Mads F Bertelsen; Nathan Wales; George H Balazs; M Thomas P Gilbert
Journal:  PeerJ       Date:  2016-07-27       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.